Option chain shows key data for OptiNose's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for OptiNose.

OptiNose (NASDAQ:OPTN) Stock, Option Chain

OptiNose

OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

fedex shutter

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

OPTN

This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Trade tensions weigh on oil demand

Earnings

Equities

Eurozone

Commodities

Intraday Update

AKBA

BHIL

ELEV

WINT

Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase

February's Jobs Report Could Tip An Already Nervous Market Into Correction Territory

ADAP

Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results

OptiNose Inc

Press Releases

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders

OPTN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Optinose, Inc. Is Fair to Shareholders

Legal

OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, BECN, OPTN on Behalf of Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of Shareholders

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

BECN

RDFN

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

ALT5 Sigma

Alto Neuroscience

Assertio Holdings

Bioage Labs

Biote

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Journey Medical Corporation - Common Stock

Journey Medical

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Ikena Oncology

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Cassava Sciences

scPharmaceuticals

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Third Harmonic Bio

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Veru

Ventyx Biosciences

Piper Sandler

HC Wainwright & Co.

Lake Street

BMO Capital

Jefferies

Option Care

Comments

OptiNose

OptiNose (OPTN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga